| Mr Joseph Alexander Ivey Iii, | |
|
400 Berywood Trl Nw Ste B, Cleveland, TN 37312-5288 | |
| (423) 472-3201 | |
| (423) 476-4949 |
| Full Name | Mr Joseph Alexander Ivey Iii |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 7 Years |
| Location | 400 Berywood Trl Nw Ste B, Cleveland, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376079269 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD65988 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tennova Health Care-cleveland | Cleveland, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tennessee Valley Urology Center Pc | 2062538077 | 5 |
News Archive
"Unions representing thousands of teachers and state and local government workers are bracing for the worst if Congress adopts a proposed 'Cadillac' tax on health insurance," Newsday reports.
A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology , the official journal of the American Gastroenterological Association (AGA) Institute.
When a child is diagnosed with cancer, one of the first questions the parents ask is "Will my other children get cancer?" A new study from Huntsman Cancer Institute at the University of Utah suggests the answer to that question depends on whether a family history of cancer exists. The research results were published online in the International Journal of Cancer and will appear in the November 15 print issue.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
Response Biomedical Corporation announced that it has received a notification from the U.S. Food and Drug Administration (FDA) that its NTproBNP Assay did not meet the criteria to obtain a waiver under the Clinical Laboratory Improvement Amendments of 1988.
› Verified 7 days ago
| Entity Name | Tennessee Valley Urology Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538173232 PECOS PAC ID: 2062538077 Enrollment ID: O20100928000567 |
News Archive
"Unions representing thousands of teachers and state and local government workers are bracing for the worst if Congress adopts a proposed 'Cadillac' tax on health insurance," Newsday reports.
A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology , the official journal of the American Gastroenterological Association (AGA) Institute.
When a child is diagnosed with cancer, one of the first questions the parents ask is "Will my other children get cancer?" A new study from Huntsman Cancer Institute at the University of Utah suggests the answer to that question depends on whether a family history of cancer exists. The research results were published online in the International Journal of Cancer and will appear in the November 15 print issue.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
Response Biomedical Corporation announced that it has received a notification from the U.S. Food and Drug Administration (FDA) that its NTproBNP Assay did not meet the criteria to obtain a waiver under the Clinical Laboratory Improvement Amendments of 1988.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Joseph Alexander Ivey Iii, 400 Berywood Trl Nw Ste B, Cleveland, TN 37312-5288 Ph: (423) 472-3201 | Mr Joseph Alexander Ivey Iii, 400 Berywood Trl Nw Ste B, Cleveland, TN 37312-5288 Ph: (423) 472-3201 |
News Archive
"Unions representing thousands of teachers and state and local government workers are bracing for the worst if Congress adopts a proposed 'Cadillac' tax on health insurance," Newsday reports.
A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology , the official journal of the American Gastroenterological Association (AGA) Institute.
When a child is diagnosed with cancer, one of the first questions the parents ask is "Will my other children get cancer?" A new study from Huntsman Cancer Institute at the University of Utah suggests the answer to that question depends on whether a family history of cancer exists. The research results were published online in the International Journal of Cancer and will appear in the November 15 print issue.
bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.
Response Biomedical Corporation announced that it has received a notification from the U.S. Food and Drug Administration (FDA) that its NTproBNP Assay did not meet the criteria to obtain a waiver under the Clinical Laboratory Improvement Amendments of 1988.
› Verified 7 days ago
Daniel Box, Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Berywood Trl Nw Ste B, Cleveland, TN 37312 Phone: 423-472-3201 Fax: 423-476-4949 | |
Edward M Mcintire Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Berywood Trl Nw, Suite B, Cleveland, TN 37312 Phone: 423-472-3201 Fax: 423-476-4949 | |
Dr. Stephen W Jackson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Berywood Trl Nw, Suite B, Cleveland, TN 37312 Phone: 423-472-3201 Fax: 423-476-4949 | |
Clyde Alexander Kyle, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 448 Kyle Ln Nw, Cleveland, TN 37312 Phone: 423-400-7038 | |
Dr. Christopher C Thacker, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 400 Berywood Trl Nw, Suite B, Cleveland, TN 37312 Phone: 423-472-3201 Fax: 423-476-4949 | |
Dr. Grant Pegram Simmons, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 400 Berywood Trl Nw Ste B, Cleveland, TN 37312 Phone: 423-472-3201 Fax: 423-476-4949 |